Immune responses to therapeutic transgenes are a potential hurdle to treat monogenic muscle disorders. These responses result from the neutralizing activity of transgene-specific B cells and cytotoxic T cells recruited upon gene transfer. We explored here how dual muscle-liver expression of a foreign transgene allows muscle transgene engraftment after adenoassociated viral vector delivery. We found in particular that induction of transgene-specific tolerance is imposed by concurrent muscle and liver targeting, resulting in the absence of CD8+ T cell responses to the transgene. This tolerance can be temporally decoupled, because transgene engraftment can be achieved in muscle weeks after liver transduction. Importantly, transgene-specific CD8+ T cell tolerance can be established despite preexisting immunity to the transgene. Whenever preexisting, transgene-specific CD4+ and CD8+ memory T cell responses are present, dual muscle-liver transduction turns polyclonal, transgene-specific CD8+ T cells into typically exhausted T cells with high programmed cell death 1 (PD-1) expression and lack of IFN-γ production. Our results demonstrate that successful transduction of muscle tissue can be achieved through liver-mediated control of humoral and cytotoxic T cell responses, even in the presence of preexisting immunity to the muscle-associated transgene.
Laurent Bartolo, Stéphanie Li Chung Tong, Pascal Chappert, Dominique Urbain, Fanny Collaud, Pasqualina Colella, Isabelle Richard, Giuseppe Ronzitti, Jocelyne Demengeot, David A. Gross, Federico Mingozzi, Jean Davoust
Title and authors | Publication | Year |
---|---|---|
Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver
Louisa Jauze, Mallaury. Vie, Quentin Miagoux, Lucille Rossiaud, Patrice Vidal, Valle Montalvo-Romeral, Margot Jarrige, Helene Polveche, Justine Nozi, Pierre-Romain Le Brun, Jeremy Rouillon, Fanny Collaud, Fanny Bordier, Emilie Bertil-Froidevaux, Christophe Georger, Laetitia Wittenberghe, Adeline Miranda, Nathalie Daniele, Lucile Hoch, Xavier Nissan, Giuseppe Ronzitti |
JCI Insight | 2024 |
Role of FoxP3+ Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy
Muñoz-Melero M, Biswas M |
Human Gene Therapy | 2024 |
Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model
Krotova K, Kuoch (Yoshitomi) H, Caine C, Aslanidi G |
2023 | |
AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy
Jacobs R, Dogbey MD, Mnyandu N, Neves K, Barth S, Arbuthnot P, Maepa MB |
Microorganisms | 2023 |
Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog
W Shao, J Sun, X Chen, A Dobbins, E Merricks, R Samulski, T Nichols, C Li |
Frontiers in pharmacology | 2022 |
Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1
Rossignol J, Belaid Z, Fouquet G, Guillem F, Rignault R, Milpied P, Renand A, Coman T, D\u2019Aveni M, Dussiot M, Colin E, Levy J, Carvalho C, Goudin N, Cagnard N, Côté F, Babdor J, Bhukhai K, Polivka L, Bigorgne AE, Halse H, Marabelle A, Mouraud S, Lepelletier Y, Maciel TT, Rubio MT, Heron D, Robert C, Girault I, Lebeherec D, Scoazec JY, Moura I, Condon L, Weimershaus M, Pages F, Davoust J, Gross D, Hermine O |
iScience | 2022 |
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
K Rapti, D Grimm |
Frontiers in immunology | 2021 |
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
DL Wagner, L Peter, M Schmueck-Henneresse |
Gene Therapy | 2021 |
Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates
H Costa-Verdera, F Collaud, CR Riling, P Sellier, JM Nordin, GM Preston, U Cagin, J Fabregue, S Barral, M Moya-Nilges, J Krijnse-Locker, L van Wittenberghe, N Daniele, B Gjata, J Cosette, C Abad, M Simon-Sola, S Charles, M Li, M Crosariol, T Antrilli, WJ Quinn, DA Gross, O Boyer, XM Anguela, SM Armour, P Colella, G Ronzitti, F Mingozzi |
Nature Communications | 2021 |
Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles
PO Ilyinskii, CJ Roy, J LePrevost, GL Rizzo, TK Kishimoto |
Frontiers in immunology | 2021 |
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
HC Verdera, K Kuranda, F Mingozzi |
Molecular Therapy | 2020 |
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
G Ronzitti, DA Gross, F Mingozzi |
Frontiers in immunology | 2020 |
Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back
L Buscara, DA Gross, N Daniele |
Journal of Personalized Medicine | 2020 |
Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
JM Martinez-Navio, SP Fuchs, DE Mendes, EG Rakasz, G Gao, JD Lifson, RC Desrosiers |
Frontiers in immunology | 2020 |
Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle
J Poupiot, HC Verdera, R Hardet, P Colella, F Collaud, L Bartolo, J Davoust, P Sanatine, F Mingozzi, I Richard, G Ronzitti |
Molecular Therapy — Methods & Clinical Development | 2019 |
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
NF Nidetz, MC McGee, LV Tse, C Li, L Cong, Y Li, W Huang |
Pharmacology & Therapeutics | 2019 |